ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.

Area of Science:

• Medicinal Chemistry
• Oncology
• Biochemistry

Background:

• Geranylgeranyl diphosphate synthase (GGDPS) is a therapeutic target in multiple myeloma due to its role in malignant plasma cell function.
• Inhibiting GGDPS disrupts protein geranylgeranylation, impairing intracellular protein trafficking essential for myeloma cell survival and protein secretion.

Purpose of the Study:

• To synthesize and evaluate novel ω-hydroxy analogues of GGDPS inhibitors for improved selective delivery to plasma cells.
• To assess the enzymatic and cellular activity of these new analogues and their potential for targeted multiple myeloma treatment.

Main Methods:

• Synthesis of new isoprenoid triazole bisphosphonate analogues incorporating an ω-hydroxy group.
• Enzymatic assays to determine GGDPS inhibitory activity of the novel analogues.
• Cellular activity assays and conjugation of a lead inhibitor to hyaluronic acid (HA) for targeted delivery studies.

Main Results:

• The incorporation of an ω-hydroxy group minimally affected the GGDPS inhibitory potency of the bisphosphonate compounds.
• Conjugation of an ω-hydroxy GGDPS inhibitor to hyaluronic acid significantly enhanced its cellular activity.
• These findings support the development of HA-conjugated GGDPS inhibitors for targeted multiple myeloma therapy.

Conclusions:

• Novel ω-hydroxy GGDPS inhibitors retain significant enzymatic activity and can be effectively conjugated to hyaluronic acid.
• HA-conjugated GGDPS inhibitors demonstrate enhanced cellular activity, paving the way for in vivo studies on targeted drug delivery.
• This strategy holds potential for developing more effective and selective treatments for multiple myeloma.